Olivia C./LinkedIn
Mar 26, 2026, 17:14
Olivia C.: Pfizer’s mRNA BNT162b2 Vaccine Does Not Induce High Levels of Inflammation
Olivia C., Business Development Manager at Pfizer, shared a post on LinkedIn:
“Precise data on changes in hematological parameters in vaccinated patients are essential to accurately reflect advancements in medical technology.
Infections can cause significant changes in certain hematological parameters and exacerbate inflammatory responses, such as the neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), and ferritin levels.
In contrast, Pfizer’s mRNA-based BNT162b2 vaccine does not induce high levels of inflammation.”
Stay updated with Hemostasis Today.
-
Mar 26, 2026, 17:15Shalom Zwiebel: Clinical Practice Evaluating PRP Systems and Supply Partners
-
Mar 26, 2026, 17:03Tilden Sokoloff: PRP Injections Enhance Sexual Function in Premenopausal Women
-
Mar 26, 2026, 17:02Mahesan Subramaniam: Japan Brings Mitochondrial Therapy to the Frontline of Cardiology
-
Mar 26, 2026, 17:01Kanishk Kumar: Discovering The Newest Advances in Hypercholesterolemia Research
-
Mar 26, 2026, 17:00Ifeanyichukwu Ifechidere: Breaking the INR Myth in Liver Disease
-
Mar 26, 2026, 16:57Georgiana Toma: Why Nutrition is a Hematologist’s Secret Weapon
-
Mar 26, 2026, 16:56Anu Anna Babu: Which DOAC is Safer for Patients With Acute Venous Thromboembolism?
-
Mar 26, 2026, 16:39Faizan Khan: Cold Agglutinins and Their Effects on CBC Results
-
Mar 26, 2026, 16:38Strengthening Research and Partnerships at THSNA 2026 – NBDF